

2017 Prescription Drug EHB-Benchmark Plan Benefit Drug Count

Category Class ID	Category	Class	Current RX Count	Proposed RX Count	Difference
1	Analgesics	Nonsteroidal Anti-inflammatory Drugs	20	13	-7
2	Analgesics	Opioid Analgesics, Long-acting	11	4	-7
3	Analgesics	Opioid Analgesics, Short-acting	14	7	-7
4	Anesthetics	Local Anesthetics	3	2	-1
5	Anti-Addiction/ Substance Abuse Treatment Agents	Alcohol Deterrents/Anti-craving	2	3	1
6	Anti-Addiction/ Substance Abuse Treatment Agents	Opioid Dependence Treatments	2	1	-1
7	Anti-Addiction/ Substance Abuse Treatment Agents	Opioid Reversal Agents	0	0	0
8	Anti-Addiction/ Substance Abuse Treatment Agents	Smoking Cessation Agents	3	3	0
9	Antibacterials	Aminoglycosides	5	4	-1
10	Antibacterials	Antibacterials, Other	15	11	-4
11	Antibacterials	Beta-lactam, Cephalosporins	10	6	-4
12	Antibacterials	Beta-lactam, Other	1	1	0
13	Antibacterials	Beta-lactam, Penicillins	5	5	0
14	Antibacterials	Macrolides	5	4	-1
15	Antibacterials	Quinolones	9	6	-3
16	Antibacterials	Sulfonamides	5	4	-1
17	Antibacterials	Tetracyclines	4	4	0
18	Anticonvulsants	Anticonvulsants, Other	5	4	-1
19	Anticonvulsants	Calcium Channel Modifying	4	2	-2
20	Anticonvulsants	Gamma-aminobutyric Acid (GABA) Augmenting Agents	6	4	-2
21	Anticonvulsants	Glutamate Reducing Agents	3	3	0
22	Anticonvulsants	Sodium Channel Agents	8	6	-2
23	Antidementia Agents	Antidementia Agents, Other	1	1	0
24	Antidementia Agents	Cholinesterase Inhibitors	3	3	0
25	Antidementia Agents	N-methyl-D-aspartate (NMDA) Receptor Antagonist	1	1	0
26	Antidepressants	Antidepressants, Other	8	6	-2
27	Antidepressants	Monoamine Oxidase Inhibitors	4	2	-2
28	Antidepressants	SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)	13	9	-4
29	Antidepressants	Tricyclics	9	6	-3
30	Antiemetics	Antiemetics, Other	9	7	-2
31	Antiemetics	Emetogenic Therapy Adjuncts	6	3	-3
32	Antifungals	No USP Class	22	12	-10

33	Antigout Agents	No USP Class	6	6	0
34	Anti-inflammatory Agents	Glucocorticoids	25	16	-9
35	Anti-inflammatory Agents	Nonsteroidal Anti-inflammatory Drugs	20	13	-7
36	Antimigraine Agents	Ergot Alkaloids	2	1	-1
37	Antimigraine Agents	Prophylactic	3	2	-1
38	Antimigraine Agents	Serotonin (5-HT) 1b/1d Receptor Agonists	7	4	-3
39	Antimyasthenic Agents	Parasympathomimetics	2	1	-1
40	Antimycobacterials	Antimycobacterials, Other	2	2	0
41	Antimycobacterials	Antituberculars	11	4	-7
42	Antineoplastics	Alkylating Agents	3	4	1
43	Antineoplastics	Antiandrogens	3	3	0
44	Antineoplastics	Antiangiogenic Agents	3	3	0
45	Antineoplastics	Antiestrogens/Modifiers	3	2	-1
46	Antineoplastics	Antimetabolites	4	4	0
47	Antineoplastics	Antineoplastics, Other	4	4	0
48	Antineoplastics	Aromatase Inhibitors, 3rd Generation	3	3	0
49	Antineoplastics	Enzyme Inhibitors	6	3	-3
50	Antineoplastics	Molecular Target Inhibitors	16	15	-1
51	Antineoplastics	Monoclonal Antibody/Antibody-Drug Conjugate	1	0	-1
52	Antineoplastics	Retinoids	3	1	-2
53	Antineoplastics	Treatment Adjuncts	0	0	0
54	Antiparasitics	Anthelmintics	3	3	0
55	Antiparasitics	Antiprotozoals	11	6	-5
56	Antiparasitics	Pediculicides/Scabicides	5	2	-3
57	Antiparkinson Agents	Anticholinergics	2	2	0
58	Antiparkinson Agents	Antiparkinson Agents, Other	3	2	-1
59	Antiparkinson Agents	Dopamine Agonists	4	3	-1
60	Antiparkinson Agents	Dopamine Precursors/ L-Amino Acid Decarboxylase Inhibitors	2	2	0
61	Antiparkinson Agents	Monoamine Oxidase B (MAO-B) Inhibitors	2	1	-1
62	Antipsychotics	1st Generation/Typical	10	9	-1
63	Antipsychotics	2nd Generation/Atypical	8	5	-3
64	Antipsychotics	Treatment-Resistant	1	1	0
65	Antispasticity Agents	No USP Class	4	4	0
66	Antivirals	Anti-cytomegalovirus (CMV) Agents	2	2	0
67	Antivirals	Anti-hepatitis B (HBV) Agents	7	7	0
68	Antivirals	Anti-hepatitis C (HCV) Agents, Direct Acting	0	0	0
69	Antivirals	Anti-hepatitis C (HCV) Agents, Other	0	0	0
70	Antivirals	Antitherpetic Agents	5	3	-2

71	Antivirals	Anti-HIV Agents, Integrase Inhibitors (INSTI)	3	2	-1
72	Antivirals	Anti-HIV Agents, Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI)	5	5	0
73	Antivirals	Anti-HIV Agents, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTI)	13	12	-1
74	Antivirals	Anti-HIV Agents, Other	3	3	0
75	Antivirals	Anti-HIV Agents, Protease Inhibitors	9	9	0
76	Antivirals	Anti-influenza Agents	4	4	0
77	Anxiolytics	Anxiolytics, Other	4	3	-1
78	Anxiolytics	Benzodiazepines	0	0	0
79	Anxiolytics	SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)	5	5	0
80	Bipolar Agents	Bipolar Agents, Other	6	6	0
81	Bipolar Agents	Mood Stabilizers	5	5	0
82	Blood Glucose Regulators	Antidiabetic Agents	20	13	-7
83	Blood Glucose Regulators	Glycemic Agents	1	1	0
84	Blood Glucose Regulators	Insulins	8	7	-1
85	Blood Products/ Modifiers/ Volume Expanders	Anticoagulants	7	7	0
86	Blood Products/ Modifiers/ Volume Expanders	Blood Formation Modifiers	6	6	0
87	Blood Products/ Modifiers/ Volume Expanders	Hemostasis Agents	0	0	0
88	Blood Products/ Modifiers/ Volume Expanders	Platelet Modifying Agents	8	6	-2
89	Cardiovascular Agents	Alpha-adrenergic Agonists	4	4	0
90	Cardiovascular Agents	Alpha-adrenergic Blocking Agents	4	4	0
91	Cardiovascular Agents	Angiotensin II Receptor Antagonists	7	3	-4
92	Cardiovascular Agents	Angiotensin-converting Enzyme (ACE) Inhibitors	10	10	0
93	Cardiovascular Agents	Antiarrhythmics	10	10	0
94	Cardiovascular Agents	Beta-adrenergic Blocking Agents	13	7	-6
95	Cardiovascular Agents	Calcium Channel Blocking Agents	9	5	-4
96	Cardiovascular Agents	Cardiovascular Agents, Other	5	2	-3
97	Cardiovascular Agents	Diuretics, Carbonic Anhydrase Inhibitors	2	2	0

98	Cardiovascular Agents	Diuretics, Loop	4	3	-1
99	Cardiovascular Agents	Diuretics, Potassium-sparing	4	3	-1
100	Cardiovascular Agents	Diuretics, Thiazide	6	5	-1
101	Cardiovascular Agents	Dyslipidemics, Fibric Acid Derivatives	2	2	0
102	Cardiovascular Agents	Dyslipidemics, HMG CoA Reductase Inhibitors	7	4	-3
103	Cardiovascular Agents	Dyslipidemics, Other	8	7	-1
104	Cardiovascular Agents	Vasodilators, Direct-acting	4	2	-2
105	Cardiovascular Agents	Vasodilators, Direct-acting Arterial/Venous	3	3	0
106	Central Nervous System Agents	Attention Deficit Hyperactivity Disorder Agents, Amphetamines	4	3	-1
107	Central Nervous System Agents	Attention Deficit Hyperactivity Disorder Agents, Non-amphetamines	4	4	0
108	Central Nervous System Agents	Central Nervous System, Other	10	5	-5
109	Central Nervous System Agents	Fibromyalgia Agents	3	1	-2
110	Central Nervous System Agents	Multiple Sclerosis Agents	7	5	-2
111	Dental and Oral Agents	No USP Class	7	7	0
112	Dermatological Agents	No USP Class	84	44	-40
113	Electrolytes/ Minerals/ Metals/ Vitamins	Electrolyte/Mineral Replacement	0	0	0
114	Electrolytes/ Minerals/ Metals/ Vitamins	Electrolyte/Mineral/Metal Modifiers	0	0	0
115	Electrolytes/ Minerals/ Metals/ Vitamins	Phosphate Binders	0	0	0
116	Electrolytes/ Minerals/ Metals/ Vitamins	Vitamins	0	0	0
117	Gastrointestinal Agents	Antispasmodics, Gastrointestinal	4	2	-2
118	Gastrointestinal Agents	Gastrointestinal Agents, Other	10	8	-2
119	Gastrointestinal Agents	Histamine2 (H2) Receptor Antagonists	4	2	-2
120	Gastrointestinal Agents	Irritable Bowel Syndrome Agents	3	3	0
121	Gastrointestinal Agents	Laxatives	4	1	-3
122	Gastrointestinal Agents	Protectants	2	2	0
123	Gastrointestinal Agents	Proton Pump Inhibitors	6	2	-4
124	Genetic or Enzyme Disorder: Replacement, Modifiers, Treatment	No USP Class	0	0	0
125	Genitourinary Agents	Antispasmodics, Urinary	7	3	-4
126	Genitourinary Agents	Benign Prostatic Hypertrophy Agents	9	6	-3
127	Genitourinary Agents	Genitourinary Agents, Other	7	3	-4

128	Hormonal Agents, Stimulant/ Replacement/ Modifying (Adrenal)	No USP Class	30	20	-10
129	Hormonal Agents, Stimulant/ Replacement/ Modifying (Pituitary)	No USP Class	5	3	-2
130	Hormonal Agents, Stimulant/ Replacement/ Modifying (Prostaglandins)	No USP Class	1	1	0
131	Hormonal Agents, Stimulant/ Replacement/ Modifying (Sex Hormones/ Modifiers)	Anabolic Steroids	2	1	-1
132	Hormonal Agents, Stimulant/ Replacement/ Modifying (Sex Hormones/ Modifiers)	Androgens	3	3	0
133	Hormonal Agents, Stimulant/ Replacement/ Modifying (Sex Hormones/ Modifiers)	Estrogens	14	5	-9
134	Hormonal Agents, Stimulant/ Replacement/ Modifying (Sex Hormones/ Modifiers)	Progesterone Agonists/ Antagonists	0	0	0
135	Hormonal Agents, Stimulant/ Replacement/ Modifying (Sex Hormones/ Modifiers)	Progestins	12	7	-5
136	Hormonal Agents, Stimulant/ Replacement/ Modifying (Sex Hormones/ Modifiers)	Selective Estrogen Receptor Modifying Agents	2	1	-1
137	Hormonal Agents, Stimulant/ Replacement/ Modifying (Thyroid)	No USP Class	3	2	-1
138	Hormonal Agents, Suppressant (Adrenal)	No USP Class	2	2	0
139	Hormonal Agents, Suppressant (Pituitary)	No USP Class	7	4	-3
140	Hormonal Agents, Suppressant (Thyroid)	Antithyroid Agents	2	2	0
141	Immunological Agents	Angioedema Agents	1	1	0
142	Immunological Agents	Immune Suppressants	18	13	-5
143	Immunological Agents	Immunizing Agents, Passive	0	0	0
144	Immunological Agents	Immunomodulators	17	10	-7

145	Inflammatory Bowel Disease Agents	Aminosalicylates	2	2	0
146	Inflammatory Bowel Disease Agents	Glucocorticoids	5	5	0
147	Inflammatory Bowel Disease Agents	Sulfonamides	1	1	0
148	Metabolic Bone Disease Agents	No USP Class	13	6	-7
149	Ophthalmic Agents	Ophthalmic Agents, Other	18	11	-7
150	Ophthalmic Agents	Ophthalmic Anti-allergy Agents	9	2	-7
151	Ophthalmic Agents	Ophthalmic Antiglaucoma Agents	18	12	-6
152	Ophthalmic Agents	Ophthalmic Anti-inflammatories	11	6	-5
153	Ophthalmic Agents	Ophthalmic Prostaglandin and Prostanoid Analogs	3	3	0
154	Otic Agents	No USP Class	8	6	-2
155	Respiratory Tract/ Pulmonary Agents	Antihistamines	10	5	-5
156	Respiratory Tract/ Pulmonary Agents	Anti-inflammatories, Inhaled Corticosteroids	8	5	-3
157	Respiratory Tract/ Pulmonary Agents	Antileukotrienes	3	1	-2
158	Respiratory Tract/ Pulmonary Agents	Bronchodilators, Anticholinergic	4	2	-2
159	Respiratory Tract/ Pulmonary Agents	Bronchodilators, Sympathomimetic	11	6	-5
160	Respiratory Tract/ Pulmonary Agents	Cystic Fibrosis Agents	3	3	0
161	Respiratory Tract/ Pulmonary Agents	Mast Cell Stabilizers	1	1	0
162	Respiratory Tract/ Pulmonary Agents	Phosphodiesterase Inhibitors, Airways Disease	5	5	0
163	Respiratory Tract/ Pulmonary Agents	Pulmonary Antihypertensives	8	5	-3
164	Respiratory Tract/ Pulmonary Agents	Pulmonary Fibrosis Agents	0	0	0
165	Respiratory Tract/ Pulmonary Agents	Respiratory Tract Agents, Other	2	1	-1
166	Skeletal Muscle Relaxants	No USP Class	6	3	-3
167	Sleep Disorder Agents	GABA Receptor Modulators	3	2	-1
168	Sleep Disorder Agents	Sleep Disorders, Other	5	2	-3
Total # of Drugs Covered			1072	731	-341